Condition: Palmoplantar Pustulosis · Sponsor: UCB Biopharma SRL
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
This description comes directly from the study's public registry record.
UCB Cares · +18445992273 · ucbcares@ucb.com
Always discuss trial participation with your own doctor first.
| Ppp001 50754 | Birmingham, Alabama, United States | Recruiting |
| Ppp001 50746 | Coral Gables, Florida, United States | Recruiting |
| Ppp001 50757 | Auburn Hills, Michigan, United States | Recruiting |
| Ppp001 50745 | Columbus, Ohio, United States | Recruiting |
| Ppp001 50202 | Fairborn, Ohio, United States | Recruiting |
| Ppp001 50744 | Oklahoma City, Oklahoma, United States | Recruiting |
| Ppp001 50233 | Barrie, Canada | Recruiting |
| Ppp001 50354 | Calgary, Canada | Recruiting |
| Ppp001 50749 | Fredericton, Canada | Recruiting |
| Ppp001 50765 | London, Canada | Recruiting |
| Ppp001 50740 | Québec, Canada | Recruiting |
| Ppp001 50752 | Red Deer, Canada | Recruiting |
+ 75 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219420